12:00 AM
Mar 31, 2014
 |  BC Week In Review  |  Company News  |  Deals

TapImmune, Mayo Clinic deal

TapImmune signed an exclusive option agreement with Mayo for peptide epitopes targeting folate receptor 1 ( FOLR1; FR-alpha) in breast and ovarian cancer. TapImmune said...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >